Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an
inadequate response to ongoing ADT.